Opinion|Videos|December 5, 2024
Behind the Scenes: Patient Education and Decision-Making for CAR T
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From your perspective, what are the key conversations you have with patients during this decision-making process? What are the most crucial aspects of patient education and support that you focus on? How do you help patients understand what lies ahead (eg, describe conversations, resources you utilize, etc)?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.